Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease

Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension

(2018) Guadalupe Garcia-Tsao et al.   HEPATOLOGY

Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH

(2017) Eduardo Vilar-Gomez et al.   LIVER INTERNATIONAL

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme

(2015) Inna S. Afonina et al.   IMMUNITY

Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology

(2015) Guy Bower et al.   OBESITY SURGERY

518 Changes in Serum Cytokeratin 18 Levels Significantly Predict Changes in Liver Histology in Adults With Nonalcoholic Steatohepatitis: Results From the Pivens Trial

(2015) Raj Vuppalanchi et al.   GASTROENTEROLOGY

Caspase 3 Inactivation Protects Against Hepatic Cell Death and Ameliorates Fibrogenesis in a Diet-Induced NASH Model

(2014) Samjhana Thapaliya et al.   DIGESTIVE DISEASES AND SCIENCES

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis

(2013) J. H. Hoofnagle et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents

(2013) Maximilian Hatting et al.   HEPATOLOGY

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

(2011) Vlad Ratziu et al.   HEPATOLOGY

Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality

(2011) Zobair M. Younossi et al.   HEPATOLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of OATP transporters on pharmacokinetics

(2009) A Kalliokoski et al.   BRITISH JOURNAL OF PHARMACOLOGY